AstraZeneca’s breast cancer drug received positive momentum from European regulators despite a negative vote from an FDA advisory committee last month, according to the report. The European opinion supports the company’s continued push to secure broader access for the therapy in the region. The same update also notes that Novo Nordisk’s Wegovy (semaglutide) pill gained EU go-ahead. Together, the two decisions underscore fast-moving regulator workflows across oncology and cardiometabolic indications. For biopharma teams, the cross-regulator divergence points to the importance of assembling region-specific evidence packages and anticipating labeling differences between jurisdictions.